Last reviewed · How we verify
Seroquel IR 25mg — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Seroquel IR 25mg (Seroquel IR 25mg) — Otsuka Pharmaceutical Development & Commercialization, Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Seroquel IR 25mg TARGET | Seroquel IR 25mg | Otsuka Pharmaceutical Development & Commercialization, Inc. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Seroquel IR 25mg CI watch — RSS
- Seroquel IR 25mg CI watch — Atom
- Seroquel IR 25mg CI watch — JSON
- Seroquel IR 25mg alone — RSS
Cite this brief
Drug Landscape (2026). Seroquel IR 25mg — Competitive Intelligence Brief. https://druglandscape.com/ci/seroquel-ir-25mg. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing